Progressive change of intra‐islet GLP‐1 production during diabetes development
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background: Glucagon‐like peptide 1 (GLP‐1) and glucagon share the same precursor molecule proglucagon, but each arises from a distinct posttranslational process in a tissue‐specific manner. Recently, it has been shown that GLP‐1 is co‐expressed with glucagon in pancreatic islet cells. This study was aimed to investigate the progressive changes of GLP‐1 versus glucagon production in pancreatic islets during the course of diabetes development. Methods: Both type 1 (non‐obese diabetes mice) and type 2 (db/db mice) diabetes models were employed in this study. The mice were monitored closely for their diabetes progression and were sacrificed at different stages according to their blood glucose levels. GLP‐1 and glucagon expression in the pancreatic islets was examined using immunohistochemistry assays. Quantitative analysis was performed to evaluate the significance of the changes. Results: The ratio of GLP‐1‐expressing cells to glucagon‐expressing cells in the islets showed significant, progressive increase with the development of diabetes in db/db mice. The increase of GLP‐1 expression was in agreement with the upregulation of PC1/3 expression in these cells. Interestingly, intra‐islet GLP‐1 expression was not significantly changed during the development of type 1 diabetes in non‐obese diabetes mice. Conclusions: The study demonstrated that GLP‐1 was progressively upregulated in pancreatic islets during type 2 diabetes development. In addition, the data suggest clear differences in intra‐islet GLP‐1 production between type 1 and type 2 diabetes developments. These differences may have an effect on the clinical and pathophysiological processes of these diseases and may be a target for therapeutic approaches. Copyright © 2014 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Glucagon-like peptide 1(GLP-1) in biology and pathology
Meier, J. J., & Nauck, M. A. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.538 · Cited by 288 · cited 1×
“in the pancreas, GLP-1 stimulates insulin secretion from insulin-producing β-cells in a blood glucose-dependent manner and inhibits glucagon secretion from the glucagon-producing α-cells, thus playing an essential role in blood glucose regulation [2,3,8].”
BackgroundInsulin Regulates Glucagon-Like Peptide-1 Secretion from the Enteroendocrine L Cell
Lim, G. E., Huang, G. J., Flora, N., LeRoith, D., Rhodes, C. J., & Brubaker, P. L. (2009) · Endocrinology · doi:10.1210/en.2008-0726 · Cited by 200 · cited 7×
“Indeed, elevated glucose concentration has been shown to be a potent stimulus for GLP-1 production in both L-cells and islet cultures [2,21,28,30].”
BackgroundInfluentialMeier, J. J., Kemmeries, G., Holst, J. J., & Nauck, M. A. (2005) · Diabetes · doi:10.2337/diabetes.54.7.2212 · Cited by 146
Salehi, M., Vahl, T. P., & D'Alessio, D. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0605 · Cited by 108
Glucagon-like peptides 1 and 2 in health and disease: A review
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2013) · Peptides · doi:10.1016/j.peptides.2013.01.014 · Cited by 100
Cited by
Wang, Y., Dilidaxi, D., Wu, Y., Sailike, J., Sun, X., & Nabi, X.-H. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109914 · Cited by 270
Panaro, B. L., Yusta, B., Matthews, D., Koehler, J. A., Song, Y., Sandoval, D. A., & Drucker, D. J. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.100990 · Cited by 67
“Moreover, the development of diabetes and/or pancreatic injury has been associated with increased expression of prohormone convertase-1 (Pcsk1) in islet acells, accompanied by the enhanced biosynthesis and liberation of bioactive islet GLP-1 [15].”
BackgroundAlpha-cell paracrine signaling in the regulation of beta-cell insulin secretion
Holter, M. M., Saikia, M., & Cummings, B. P. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.934775 · Cited by 63
“reported an increase in alpha-cell PC1/3 expression and an increase in the ratio of GLP-1: glucagon alpha-cells with the onset of diabetes in db/db mice as compared to normal mice (86).”
BackgroundIntra-islet glucagon-like peptide 1
Fava, G. E., Dong, E. W., & Wu, H. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.05.016 · Cited by 45
“Up-regulation of GLP-1 in α cells has been observed in most diabetic animal models such as db/db mice, ob/ob mice, STZ-induced diabetic mice, and human T2D patients (Kilimnik et al. 2010; Marchetti et al. 2012; Nie et al. 2000; O’Malley et al. 2014; Whalley et al. 2011).”
BackgroundResultInfluentialSelf-citationEndogenous GLP-1 as a key self-defense molecule against lipotoxicity in pancreatic islets
HUANG, C., YUAN, L., & CAO, S. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2207 · Cited by 41
Metadata
- Authors
- O'Malley, T. J., Fava, G. E., Zhang, Y., Fonseca, V. A., & Wu, H.
- Venue
- Diabetes/Metabolism Research and Reviews
- Publisher
- Wiley
- Published
- 2014-11
- Volume
- 30
- Issue
- 8
- Pages
- 661-668
- ISSN
- 1520-7552 (ISSN-L)
- 1520-7560
- OpenAlex
- W1533939474
- Cited by
- 47
- References
- 7
- FWCI
- 4.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.